<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">ISRN Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">ISRN Dermatol</journal-id><journal-id journal-id-type="publisher-id">ISRN.DERMATOLOGY</journal-id><journal-title-group><journal-title>ISRN Dermatology</journal-title></journal-title-group><issn pub-type="ppub">2090-4592</issn><issn pub-type="epub">2090-4606</issn><publisher><publisher-name>International Scholarly Research Network</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22957266</article-id><article-id pub-id-type="pmc">3431102</article-id><article-id pub-id-type="doi">10.5402/2012/863692</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Effectiveness of Glycyrrhizinic Acid (Glizigen) and an Immunostimulant (Viusid) to Treat Anogenital Warts</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dom&#x000ed;nguez G&#x000f3;mez</surname><given-names>Jos&#x000e9;</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sim&#x000f3;n</surname><given-names>Ram&#x000f3;n Daniel</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Abreu Daniel</surname><given-names>Alfredo</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zelenkova</surname><given-names>Hana</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Hospital Cl&#x000ed;nico Quir&#x000fa;rgico Comandante Manuel Fajardo, Havana, Cuba</aff><aff id="I2"><sup>2</sup>Private Clic of dermatovenerologie, Svidnik, Slovakia</aff><author-notes><corresp id="cor1">*Hana Zelenkova: <email>zelenkova@vl.sk</email></corresp><fn fn-type="other"><p>Academic Editors: E. Nagore and R. A. Schwartz</p></fn></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>14</day><month>8</month><year>2012</year></pub-date><volume>2012</volume><elocation-id>863692</elocation-id><history><date date-type="received"><day>21</day><month>3</month><year>2012</year></date><date date-type="accepted"><day>3</day><month>5</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2012 Jos&#x000e9; Dom&#x000ed;nguez G&#x000f3;mez et al.</copyright-statement><copyright-year>2012</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Genital warts are benign proliferations of skin and mucosa caused by the human papillomavirus infection (hereinafter referred to as HPV). It is one of the most common sexually transmitted diseases in the world, whose incidence rate has increased in the last three decades. Current treatment involves the physical destruction of the infected cells. The fact that there are many different types of treatment goes to show that none of them are uniformly effective or directly antiviral. <italic>Objective</italic>. Demonstrate the efficacy of Glizigen in the III-phase clinical trial combined with a food supplement (VIUSID) formulated to boost the immune system when treating external anogenital warts. <italic>Design</italic>. 100 patients clinically diagnosed with anogenital lesions were included in the trial and assigned to two groups of 50 individuals. Those from one group where treated with Glizigen and Viusid and those from the other group with 25% podophyllin in alcohol, the results from each were then compared. <italic>Results</italic>. The combined Glizigen-Viusid treatment was seen to have an 87.5% efficacy rate, which was slightly more than that of the treatment with podophyllin, and there were hardly any adverse reactions reported during the treatment. <italic>Conclusions</italic>. the combined Glizigen-Viusid treatment was effective in treating genital warts.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Genital warts are benign proliferations of skin and mucosa caused by the human papillomavirus infection. These viruses do not have any acute signs or symptoms, just the slow growth of lesions that can be subclinical for long periods of time [<xref rid="B1" ref-type="bibr">1</xref>]. They are a group of DNA viruses that belong to the Papovaviridae family, they are nonenveloped, and they cause all kinds of warts and a great deal of tropism on different parts of the body [<xref rid="B2" ref-type="bibr">2</xref>]. Up to 150 different types have been identified and around 40 of these infect the anogenital tract in men and women [<xref rid="B3" ref-type="bibr">3</xref>]. They are classified as being either high or low oncogenic risk types, the latter includes types 6 and 11, which are responsible of the appearance of condylomata in more than 90% of the cases [<xref rid="B4" ref-type="bibr">4</xref>].</p><p>Genital warts is one of the most common sexually transmitted diseases in the world, its incidence rate has increased in the last three decades; 600 million individuals are thought to be infected and 190 million with clinical infection. There are not any official statistics on the prevalence of the HPV infection in Latin America [<xref rid="B5" ref-type="bibr">5</xref>]. In Cuba, 83,521 cases were reported in the period 1990&#x02013;2003 [<xref rid="B6" ref-type="bibr">6</xref>].</p><p>It is transmitted through sexual intercourse, trauma with contaminated material, contact with surfaces that are infected with the virus, and, occasionally, vertical transmission (trans placental) or perinatal (contact with the birth canal). The incubation period is between 2 to 9 months [<xref rid="B7" ref-type="bibr">7</xref>&#x02013;<xref rid="B8b" ref-type="bibr">9</xref>]. The disease is not as contagious in the early stages [<xref rid="B9" ref-type="bibr">10</xref>&#x02013;<xref rid="B11" ref-type="bibr">12</xref>]. </p><p>Lesions are located on the penis, vulva, scrotum, perineum, and the perianal area; the cervix, urethra, anus, mouth; and also in the conjunctiva, the nose, and the larynx [<xref rid="B7" ref-type="bibr">7</xref>]. They vary in appearance; some are pinpoint papules, others are cauliflower-like masses. They can be red, pink, or skin colour [<xref rid="B12" ref-type="bibr">13</xref>]. Depending on the size and the anatomical location they can be painful, friable, or itchy. Even though they are usually asymptomatic, they do have a considerable psychological impact on the sufferer.</p><p>The diagnosis is based on the clinical examination. The use of acetic acid (3&#x02013;5%) improves the detection of these lesions, biopsy [<xref rid="B7" ref-type="bibr">7</xref>], detecting low serum antibody titres, immunohistochemical analysis of the HPV structural proteins (confirmatory method) by DNA hybridization technique and finding the nucleic acid of a virus (DNA or RNA) or the capsid protein as a definitive diagnosis [<xref rid="B10" ref-type="bibr">11</xref>].</p><p>Current treatment involves the physical destruction of the infected cells, but the fact that there are many types of treatment goes to show that none of these are uniformly effective or directly antiviral. As the preferred treatment involves eliminating the visible wart, there is no evidence that shows that the existing treatment available eradicates the HPV infection, reduces the infectivity, or modifies the natural history of the infection [<xref rid="B10" ref-type="bibr">11</xref>].</p><p>The nonsurgical therapy includes the interferon (topical, intralesional, or systematic), podofilox, and imiquimod topical, and the most used (more experience) are podophyllin and the trichloroacetic acid. There are others like intralesional bleomycin, retinoic acid, cantharidin, 5-fluorouracil cream, and the interferon alfa-2b. 1% of Cidofovir, HSPE [<xref rid="B13" ref-type="bibr">14</xref>, <xref rid="B14" ref-type="bibr">15</xref>], HPMPC (the analogue of the acyclic nucleoside phosphonates) [<xref rid="B11" ref-type="bibr">12</xref>, <xref rid="B15" ref-type="bibr">16</xref>], arotinoid ethyl ester (3rd generation polyaromatic retinoids) [<xref rid="B12" ref-type="bibr">13</xref>], zinc sulfate (10&#x02009;mg/kg/day) [<xref rid="B16" ref-type="bibr">17</xref>], dinitrochlorobenzene (DNCB), and the diphenylcyclopropenone (which are thought to stimulate local immunity). Recently, cimetidine has been distinguished for being successful in treating skin warts, especially in children. Cytokines [<xref rid="B1" ref-type="bibr">1</xref>] and intralesional injection of Candida antigen by immunotherapy are also administered [<xref rid="B17" ref-type="bibr">18</xref>]; not long ago (June 2006) the FDA (Food Drugs Administration) approved the vaccine, that the pharmaceutical company Merck sells under the name of GARDASIL (it blocks the 4 HPV strains of the infection), that can be used on women and girls aged between 9 and 26 [<xref rid="B18" ref-type="bibr">19</xref>].</p><p>Surgical treatment includes cryotherapy, surgical excision and cryosurgery with laser, the CO<sub>2</sub> laser, and electrofulguration [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B7" ref-type="bibr">7</xref>].</p><p>The types of HPV causative agents [<xref rid="B19" ref-type="bibr">20</xref>], the appearance of the infection, and how it is treated are the same in Cuba as in the rest of the world. The most commonly used specific treatments are: Podophyllin (10&#x02013;25%) in alcohol solution or in tincture of benzoin, bi- or trichloroacetic acid (80&#x02013;90%) in alcohol solution, electrofulguration (in isolated lesions), cryotherapy, and surgical exeresis [<xref rid="B20" ref-type="bibr">21</xref>&#x02013;<xref rid="B22" ref-type="bibr">23</xref>]. In 2005, a clinical trial was carried out to determine the efficacy of podophyllin, trichloroacetic acid, and cryosurgery although significant differences were not found when these were used to treat external anogenital warts. </p><p>Alternative therapy is part of the medical arsenal available to treat many of the diseases that we are faced with on a daily basis. By using the aforementioned knowledge and that obtained from other recent studies, Catalysis Laboratories has developed a product called GLIZIGEN. One of its main active ingredients is glycyrrhizinic acid, which is a substance found in the <italic>Glycyrrhiza glabra roo</italic>t, commonly known as &#x0201c;sweet root&#x0201d;, that was used way back in ancient Egypt and China to treat respiratory infections and as an anti-inflammatory. Modern-day research has demonstrated its anti-inflammatory activity, its antiulcerative and antiviral effect. The former (0.1&#x02009;g in 100&#x02009;mL of the vehicle) interacts with viral proteins, which according to the stage of the viral infection can lead to the inactivation of extracellular free virus particles, the prevention of the intracellular decapsulation of infectious particles, and the deterioration of the assembling capacity of the structural components of the virus.</p><p>Its beneficial effects are enhanced by molecular activation that considerably improves the biological activity of the antioxidizing molecules and that of all other molecules that contain carboxyl groups in their structure; it can also make antiviral activity up to 10,000 times as effective.</p><p>Clinical studies carried out at dermatovenerology and gynecology clinics confirm its effectiveness. It does not produce any complications in pregnant women; it's 100% effective in the early stages of the disease and 90% in relapse cases; it is very well tolerated, it does not cause skin irritation, and it is quite innocuous. No interactions with other pharmacological preparations have been documented. One of these is Viusid, a food supplement that has been especially designed to help balance and stimulate the functions of the immune system. It contains antiviral agents, antioxidants, and anti-free radicals that are essential for our health as they boost the defenses of the immune system and strengthen the whole organism.</p><p>Given the prevalence of this STI, its biological and psychological repercussions, the lack of effective medicine, and the new therapeutic possibilities that provide us with alternative types of treatment, a study was organised so as to evaluate how successful the combination of Glizigen-Viusid is in treating external genital warts.</p></sec><sec id="sec2"><title>2. Method</title><p>A prospective experimental clinical trial was performed with the help of Catalysis Laboratories (Madrid, Spain). The sample consisted of 100 patients who were divided up into 2 groups, each having 50 individuals who were selected according to the inclusion criteria and by simple random sampling.</p><sec id="sec2.1"><title>2.1. Method of Use for the Medicine</title><p>The lesions of all the patients were measured with a ruler and the area of skin affected was determined. Up to 10&#x02009;cm<sup>2</sup> was the limit set for members of both groups.</p><p>Members of the control group were administered podophyllin once a week for 6 weeks. At the end of this period, if the lesions had not disappeared, the treatment was changed and the subsequent results were not included in the clinical trial, those obtained during the follow-up period were not either because the patients were considered to have abandoned the clinical trial.</p><p>Members of the group that was treated with Glizigen were given written instructions on how many sprays of the product had to be applied at the out-patients unit (once spray is equal to two small squirts) according to the area of skin that was affected: 1 to 3.9&#x02009;cm<sup>2</sup>, 3 times a day; from 4 to 6.9&#x02009;cm<sup>2</sup>, 4 times a day; 7 to 10&#x02009;cm<sup>2</sup>, 5 times a day, for 8 weeks. After this period, the treatment was reviewed to see whether it should be combined or replaced by a more conventional type of treatment that depended on the specific patient, just like the procedure followed with podophyllin, in which case they were considered to have abandoned the clinical trial. Moreover, a 30&#x02009;mL dose of Viusid (syrup) was administered every 8 hours, each day, during the treatment. The patients were told to take it after meals, dissolving it in drinking water, fruit juice, or milk.</p><p>Two patients from the group treated with Glizigen decided, on their own free will, to leave the clinical trial, so 48 patients managed to complete the treatment. All the members from the control group completed the treatment.</p><p>The lesions were photodocumented at the start and at the end of the treatment. A data collection model was used (see annex) that showed the general data about the patients and the disease. The results were kept on an Excel database and were statistically processed with the EPIDAT 3.1. software.</p></sec></sec><sec id="sec3"><title>3. Results</title><p>On analysing the distribution of patients according to their age, the predominant group was clearly that consisting of patients aged between 15 and 24 (<xref ref-type="table" rid="tab1">Table 1</xref>). There were no significant differences with regard to the gender-related distribution in either of the products used (<xref ref-type="fig" rid="fig1">Figure 1</xref>). </p><p>
<xref ref-type="fig" rid="fig2">Figure 2</xref> shows the response to the treatment; a good response to both products was observed. However, the best response to both treatments was seen in the last two weeks of using them (Figures <xref ref-type="fig" rid="fig3">3</xref> and <xref ref-type="fig" rid="fig4">4</xref>). </p><p>On evaluating the correlation between curing the skin lesion and the affected area on diagnosis, less than 5&#x02009;cm<sup>2</sup> of the skin in more than 84% of the members of both groups was affected (<xref ref-type="table" rid="tab2">Table 2</xref>). With regards to discomfort mentioned by the patients during the treatment period, Glizigen was seen to be tolerated better (<xref ref-type="table" rid="tab3">Table 3</xref>). </p><p>The evolution of the lesions after applying the medicine is shown in the photos (Figures <xref ref-type="fig" rid="fig5">5</xref> and <xref ref-type="fig" rid="fig6">6</xref>).</p></sec><sec id="sec4"><title>4. Discussion</title><p>In general, response to both treatments was good, although that of Glizigen was slightly better than that of podophyllin. An analysis was carried out to see whether this difference was statistically significant for a 95% confidence interval; however the corresponding results showed it was not. International studies have produced varied efficacy responses to podophyllin that range from between 44% and 76% [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B18" ref-type="bibr">19</xref>, <xref rid="B23" ref-type="bibr">24</xref>&#x02013;<xref rid="B24b" ref-type="bibr">26</xref>] and they have had good results with high rates of healing with Glizigen, although the percentage of efficacy has not been determined [<xref rid="B25" ref-type="bibr">27</xref>&#x02013;<xref rid="B29" ref-type="bibr">31</xref>]. </p><p>Given the maximum time period established to use both products, in weeks (8 for Glizigen and 6 for podophyllin), more patients whose lesions did actually heal within this period did so in the last two weeks. In the studies analysed, we did not find any specific results that were similar to those shown in our graphs, although the time limit set for the lesions to heal in the population mean for each treatment was the same.</p><p>Even though the affected area of skin was measured in cm<sup>2</sup> in our clinical trial, which is different from the measuring unit of this variable used in other published studies, they do coincide in some respects. The majority of patients from most of the series analysed were reported to have less than 10 lesions (mainly small ones), which is understood as being a similarity. This still has to be proved by further research, [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B9" ref-type="bibr">10</xref>, <xref rid="B18" ref-type="bibr">19</xref>, <xref rid="B24a" ref-type="bibr">25</xref>, <xref rid="B24b" ref-type="bibr">26</xref>] but it could be due to the fact that there are plenty of qualified personnel available, the medical culture of the patients themselves, and because the lesions are very noticeable, especially for members of the sexually active population, so they go to the doctor before the affected area gets worse. In turn, an analysis was carried out to see whether the size of the affected area was associated with the response to the treatment. The results of such showed that these variables were independent too, as shown in the corresponding table.</p><p>The results obtained when using Glizigen coincide with those obtained by other authors using this medicine [<xref rid="B18" ref-type="bibr">19</xref>, <xref rid="B29" ref-type="bibr">31</xref>, <xref rid="B30" ref-type="bibr">32</xref>]. </p><p>Out of all the findings, the penis was the most affected genital organ in men. Almost half the patients had suffered from the lesions for 1 to 4 months, which coincides with the findings of the international reports [<xref rid="B9" ref-type="bibr">10</xref>, <xref rid="B18" ref-type="bibr">19</xref>, <xref rid="B24a" ref-type="bibr">25</xref>, <xref rid="B24b" ref-type="bibr">26</xref>, <xref rid="B31" ref-type="bibr">33</xref>]. We can conclude the following.<list list-type="order"><list-item><p>Using Glizigen together with Viusid was effective in treating the external anogenital warts.</p></list-item><list-item><p>The variables concerning age, gender, anatomical location, and the area affected by the lesions coincide with what has been reported by other researchers.</p></list-item><list-item><p>There was a good clinical response to both treatments.</p></list-item><list-item><p>The combined Glizigen-Viusid treatment was better than the treatment with podophyllin.</p></list-item><list-item><p>The effectiveness and innocuousness of Glizigen combined with Viusid in the treatment of this disease are confirmed.</p></list-item></list>
</p></sec></body><back><ref-list><ref id="B1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Douglas</surname><given-names>RL</given-names></name><name><surname> Warts</surname><given-names>JAE</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Freedberg</surname><given-names>I</given-names></name><name><surname>Eisen</surname><given-names>A</given-names></name><name><surname>Fitzpatrick</surname><given-names>T</given-names></name></person-group><source><italic>Dermatolog&#x000ed;a en Medicina General</italic></source><year>2001</year><edition>5ta edition</edition><publisher-loc>Buenos Aires, Argentina</publisher-loc><publisher-name>Editorial M&#x000e9;dica Panamericana</publisher-name></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Papiloma</surname><given-names>ZL</given-names></name></person-group><comment><ext-link ext-link-type="uri" xlink:href="http://www.facmed.unam.com">http://www.facmed.unam.com</ext-link></comment></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="other"><collab>Consenso de Papiloma Virus Humano (HPV) y Herpes Simples Virus (HSV) Genital</collab><comment><ext-link ext-link-type="uri" xlink:href="http://www.sad.org.ar">http://www.sad.org.ar</ext-link></comment></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Men&#x000e9;ndez</surname><given-names>M</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>MDL&#x000c1;</given-names></name><name><surname>vela de Oro</surname><given-names>OA</given-names></name><name><surname>Torres Ch&#x000e1;vez</surname><given-names>A</given-names></name></person-group><article-title>Actualizaci&#x000f3;n de la terap&#x000e9;utica del papilomavirus humano. Terapia convencional</article-title><source><italic>Revista Cubana de Medicina</italic></source><year>2004</year><volume>43</volume><issue>1</issue><fpage>34</fpage><lpage>41</lpage><pub-id pub-id-type="other">2-s2.0-55449134113</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Wincheids</surname><given-names>OEF</given-names></name><name><surname>Gonz&#x000e1;les</surname><given-names>AL</given-names></name></person-group><comment>Condiloma Acuminado. Gu&#x000ed;as Cl&#x000ed;nicas en Atenci&#x000f3;n primaria 2003, 3 (33), <ext-link ext-link-type="uri" xlink:href="http://www.fisterra.com.br">http://www.fisterra.com.br</ext-link></comment></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="other"><comment>Direcci&#x000f3;n Nacional de Estad&#x000ed;sticas. MINSAP. Cuba, 2004</comment></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><collab>Centers for Disease Control and Prevention</collab><article-title>Guidelines for treatment of sexually transmitted diseases</article-title><source><italic>Morbidity and Mortality Weekly Report</italic></source><year>2002</year><volume>51</volume><issue>RR06</issue><fpage>1</fpage><lpage>80</lpage></element-citation></ref><ref id="B8a"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castle</surname><given-names>PE</given-names></name><name><surname>Wacholder</surname><given-names>S</given-names></name><name><surname>Lorincz</surname><given-names>AT</given-names></name><etal/></person-group><article-title>A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women</article-title><source><italic>Journal of the National Cancer Institute</italic></source><year>2002</year><volume>94</volume><issue>18</issue><fpage>1406</fpage><lpage>1414</lpage><pub-id pub-id-type="other">2-s2.0-0037130888</pub-id><pub-id pub-id-type="pmid">12237286</pub-id></element-citation></ref><ref id="B8b"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E</given-names></name></person-group><article-title>Therapeutic potential of HPMPC as an antiviral drug</article-title><source><italic>Reviews in Medical Virology</italic></source><year>1993</year><volume>3</volume><fpage>85</fpage><lpage>96</lpage></element-citation></ref><ref id="B9"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Favre</surname><given-names>M</given-names></name><name><surname>Ramoz</surname><given-names>N</given-names></name><name><surname>Orth</surname><given-names>G</given-names></name></person-group><article-title>Human papillomaviruses: general features</article-title><source><italic>Clinics in Dermatology</italic></source><year>1997</year><volume>15</volume><issue>2</issue><fpage>181</fpage><lpage>198</lpage><pub-id pub-id-type="other">2-s2.0-0030913830</pub-id><pub-id pub-id-type="pmid">9167903</pub-id></element-citation></ref><ref id="B10"><label>11</label><element-citation publication-type="other"><collab>Centers for Disease Control and Prevention</collab><comment>Sexually transmitted diseases treatment guidelines 2002.MMWR, 51(No. RR-6):[53-57], <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/STD/treatment/">http://www.cdc.gov/STD/treatment/</ext-link></comment></element-citation></ref><ref id="B11"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Snoeck</surname><given-names>R</given-names></name><name><surname>Van Ranst</surname><given-names>M</given-names></name><etal/></person-group><article-title>Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine</article-title><source><italic>Journal of Medical Virology</italic></source><year>1995</year><volume>45</volume><issue>2</issue><fpage>230</fpage><lpage>235</lpage><pub-id pub-id-type="other">2-s2.0-0028936680</pub-id><pub-id pub-id-type="pmid">7775945</pub-id></element-citation></ref><ref id="B12"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YH</given-names></name><name><surname>Gao</surname><given-names>XH</given-names></name><name><surname>He</surname><given-names>CD</given-names></name><name><surname>Guomei</surname><given-names>Z</given-names></name><name><surname>Don</surname><given-names>ZX</given-names></name><name><surname>Chan</surname><given-names>HD</given-names></name></person-group><article-title>Detection of human papillomavirus and response to oral aratinoid ethylester in 2 cases of Darier disease</article-title><source><italic>Archives of Dermatology</italic></source><year>2001</year><volume>137</volume><fpage>695</fpage><lpage>696</lpage></element-citation></ref><ref id="B13"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>FX</given-names></name><name><surname>Manos</surname><given-names>MM</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>N</given-names></name><etal/></person-group><article-title>Prevalence of human papilloma virus in cervical cancer: a worldwide perspective</article-title><source><italic>Journal of the National Cancer Institute</italic></source><year>1995</year><volume>87</volume><issue>11</issue><fpage>796</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">7791229</pub-id></element-citation></ref><ref id="B14"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calisto</surname><given-names>D</given-names></name><name><surname>Arcangeli</surname><given-names>F</given-names></name></person-group><article-title>Topical cidofovir for condylomata acuminata of the genitalia in a 3-year-old child</article-title><source><italic>Journal of the American Academy of Dermatology</italic></source><year>2003</year><volume>49</volume><issue>6</issue><fpage>1192</fpage><lpage>1193</lpage><pub-id pub-id-type="other">2-s2.0-0344430157</pub-id></element-citation></ref><ref id="B15"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mu&#x000f1;oz</surname><given-names>N</given-names></name><name><surname>Bosch</surname><given-names>FX</given-names></name><name><surname>de Sanjos&#x000e9;</surname><given-names>S</given-names></name><etal/></person-group><article-title>Epidemiologic classification of human papillomavirus types associated with cervical cancer</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2003</year><volume>348</volume><issue>6</issue><fpage>518</fpage><lpage>527</lpage><pub-id pub-id-type="other">2-s2.0-0037421589</pub-id><pub-id pub-id-type="pmid">12571259</pub-id></element-citation></ref><ref id="B16"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Gurairi</surname><given-names>FT</given-names></name><name><surname>Al-Waiz</surname><given-names>M</given-names></name><name><surname>Sharquie</surname><given-names>KE</given-names></name></person-group><article-title>Oral zinc sulphate in the treatment of recalcitrant viral warts: randomized placebo-controlled clinical trial</article-title><source><italic>British Journal of Dermatology</italic></source><year>2002</year><volume>146</volume><issue>3</issue><fpage>423</fpage><lpage>431</lpage><pub-id pub-id-type="other">2-s2.0-0036277804</pub-id><pub-id pub-id-type="pmid">11952542</pub-id></element-citation></ref><ref id="B17"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Signore</surname><given-names>RJ</given-names></name></person-group><article-title>Candida immunotherapy of warts</article-title><source><italic>Archives of Dermatology</italic></source><year>2001</year><volume>137</volume><fpage>1250</fpage><lpage>1251</lpage></element-citation></ref><ref id="B18"><label>19</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mung&#x000ed;a</surname><given-names>MA</given-names></name></person-group><source><italic>Eficacia del &#x000e1;cido glicirric&#x000ed;nico activado, con relaci&#x000f3;n al nitr&#x000f3;geno l&#x000ed;quido, y a la combinaci&#x000f3;n de ambos, en el tratamiento del condiloma acuminado en pacientes atendidos en el Centro Nacional de Dermatolog&#x000ed;a [Tesis de Especialista]</italic></source><year>2006</year><publisher-name>Universidad Nacional Autonoma de Nicaragua, UNAN-Managua</publisher-name></element-citation></ref><ref id="B19"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soto</surname><given-names>Y</given-names></name><name><surname>Mune</surname><given-names>M</given-names></name><name><surname>Goicolea</surname><given-names>A</given-names></name></person-group><article-title>Aplicaci&#x000f3;n de la t&#x000e9;cnica de reacci&#x000f3;n en cadena de la polimerasa para la detecci&#x000f3;n de secuencias de Papillomavirus humano</article-title><source><italic>Revista Cubana de Medicina Tropical</italic></source><year>1998</year><volume>50</volume><issue>3</issue><fpage>191</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">10349442</pub-id></element-citation></ref><ref id="B20"><label>21</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Sanabria</surname><given-names>GJN</given-names></name><name><surname>M&#x000e9;rida</surname><given-names>AM</given-names></name><name><surname>Medina</surname><given-names>SV</given-names></name><name><surname>Vald&#x000e9;s</surname><given-names>PG</given-names></name></person-group><comment>2004, Prevalencia del Papiloma Humano en el cuello uterino. Pinar del R&#x000ed;o, <ext-link ext-link-type="uri" xlink:href="http://www.conganat.org/7congreso/trabajo.asp?idtrabajo=495">http://www.conganat.org/7congreso/trabajo.asp?idtrabajo=495</ext-link></comment></element-citation></ref><ref id="B21"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sintes</surname><given-names>R&#x000c1;</given-names></name></person-group><source><italic>Editorial Ciencias M&#x000e9;dicas</italic></source><year>2001</year><volume>2</volume><issue>23</issue><fpage>414</fpage><lpage>417</lpage></element-citation></ref><ref id="B22"><label>23</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Colectivo de Autores</surname><given-names>MinisteriodeSaludP&#x000fa;blica</given-names></name></person-group><source><italic>Infecciones de Transmisi&#x000f3;n Sexual, pautas para su tratamiento</italic></source><year>2004</year><publisher-loc>Ciudad Habana, Cuba</publisher-loc><publisher-name>Ministerio de Salud P&#x000fa;blica</publisher-name></element-citation></ref><ref id="B23"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Krogh</surname><given-names>G</given-names></name><name><surname>Lacey</surname><given-names>CJN</given-names></name><name><surname>Gross</surname><given-names>G</given-names></name><name><surname>Barrasso</surname><given-names>R</given-names></name><name><surname>Schneider</surname><given-names>A</given-names></name></person-group><article-title>European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts</article-title><source><italic>Sexually Transmitted Infections</italic></source><year>2000</year><volume>76</volume><issue>3</issue><fpage>162</fpage><lpage>168</lpage><pub-id pub-id-type="other">2-s2.0-0033918893</pub-id><pub-id pub-id-type="pmid">10961190</pub-id></element-citation></ref><ref id="B24a"><label>25</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Acevedo AS</surname><given-names>L</given-names></name></person-group><source><italic>Eficacia de la Podofilina, el &#x000c1;cido tricloroac&#x000e9;tico y la Criocirug&#x000ed;a en el Tratamiento de las Verrugas Genitales Externas [Tesis de Especialista]</italic></source><year>2005</year><publisher-loc>Ciudad Habana, Cuba</publisher-loc><publisher-name>ISCM-H. Facultad Comandante Manuel Piti Fajardo</publisher-name></element-citation></ref><ref id="B24b"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miracco</surname><given-names>C</given-names></name><name><surname>Palummo</surname><given-names>N</given-names></name><name><surname>Lavergne</surname><given-names>D</given-names></name><name><surname>Nyongo</surname><given-names>A</given-names></name><name><surname>Tosi</surname><given-names>P</given-names></name><name><surname>de Villiers</surname><given-names>E-M</given-names></name></person-group><article-title>Malignant melanoma: search for human papillomavirus</article-title><source><italic>Archives of Dermatology</italic></source><year>2001</year><volume>137</volume><fpage>826</fpage><lpage>827</lpage><pub-id pub-id-type="pmid">11405788</pub-id></element-citation></ref><ref id="B25"><label>27</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Luis</surname><given-names>BA</given-names></name></person-group><source><italic>Estudio multic&#x000e9;ntrico, prospectivo, abierto, controlado, sobre la eficacia, la seguridad cl&#x000ed;nica y la tolerabilidad local de la administraci&#x000f3;n repetitiva (t.i.d.) por 5 d&#x000ed;as del &#x000e1;cido glicirric&#x000ed;nico activado (Epigen) en pulverizaciones locales a pacientes cursando con herpes genital</italic></source><year>1997</year><publisher-loc>Mexico City, M&#x000e9;xico</publisher-loc><publisher-name>Hospital General de M&#x000e9;xico, Servicio de Infectolog&#x000ed;a</publisher-name></element-citation></ref><ref id="B26"><label>28</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bogatyreva</surname><given-names>II</given-names></name></person-group><source><italic>Experience in Usage of EPIGEN at Treatment of Papilloma Virus Infection of the Urogenital Duct</italic></source><year>2008</year><publisher-loc>City of Moscov</publisher-loc><publisher-name>Central Science&#x02014;Research Institute of Dermatovenereal Diseases</publisher-name></element-citation></ref><ref id="B27"><label>29</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Martin-Crevillente</surname><given-names>O</given-names></name></person-group><source><italic>Report on the Results of the Tests with the Product Epigen (Laboratories Cheminova International, S.A., Madrid). Evaluate the Effectiveness and the Tolerance of the Antiviral Preparation Epigen in Women with Papillomavirus Infection</italic></source><publisher-loc>Madrid, Spain</publisher-loc><publisher-name>Ginecologic Center,&#x0201c;Salud y Mujer&#x0201d;</publisher-name></element-citation></ref><ref id="B28"><label>30</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Espinoza</surname><given-names>A</given-names></name><name><surname>Barrag&#x000e1;n</surname><given-names>L</given-names></name></person-group><source><italic>Estudio longitudinal, prospectivo, abierto, sobre la evaluaci&#x000f3;n de la efectividad, la seguridad cl&#x000ed;nica y la tolerabilidad local de la administraci&#x000f3;n repetitiva (q.id.) por 10 d&#x000ed;as del &#x000e1;cido glicirric&#x000ed;nico activado (Epig&#x000e9;n) en pulverizaciones locales a pacientes cursando con infecci&#x000f3;n por virus del papiloma humano (HPV) a nivel del c&#x000e9;rvix uterino</italic></source><year>2004</year><publisher-loc>Mexico City, M&#x000e9;xico</publisher-loc><publisher-name>Cl&#x000ed;nica de Detecci&#x000f3;n y Tratamiento de Displasias, Universidad de Guadalajara</publisher-name></element-citation></ref><ref id="B29"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zelenkov&#x000e1;</surname><given-names>H</given-names></name><name><surname>Nejdkov&#x000e1;</surname><given-names>A</given-names></name><name><surname>&#x00160;kutilov&#x000e1;</surname><given-names>E</given-names></name><name><surname>Urb&#x000e1;ni</surname><given-names>M</given-names></name><name><surname>&#x00160;vecov&#x000e1;</surname><given-names>D</given-names></name><name><surname>Cabalov&#x000e1;</surname><given-names>J</given-names></name></person-group><article-title>Preparations containing glycyrrhizic acid employed in dermatovenereologic practice. Conclusions of an international multicentre study</article-title><source><italic>Dermatologia Kliniczna</italic></source><year>2005</year><volume>7</volume><issue>3</issue><fpage>135</fpage><lpage>139</lpage><pub-id pub-id-type="other">2-s2.0-24644509345</pub-id></element-citation></ref><ref id="B30"><label>32</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>G</given-names></name><name><surname>Domonkos</surname><given-names>A</given-names></name></person-group><article-title>Enfermedades v&#x000ed;ricas</article-title><source><italic>Tratado de Dermatolog&#x000ed;a</italic></source><year>2004</year><edition>5ta edition</edition><publisher-name>Editorial M&#x000e9;dica Panamericana</publisher-name><fpage>p. 486</fpage></element-citation></ref><ref id="B31"><label>33</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rook</surname><given-names>A</given-names></name><name><surname>Wilkinson</surname><given-names>DS</given-names></name><name><surname>Ebling</surname><given-names>FJ</given-names></name><name><surname>Champion</surname><given-names>RH</given-names></name><name><surname>Burton</surname><given-names>J</given-names></name></person-group><source><italic>Textbook of Dermatology</italic></source><year>1992</year><edition>5th edition</edition><publisher-loc>London, UK</publisher-loc><publisher-name>Blackwell Scientific</publisher-name></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Gender distribution. Hospital Manuel Fajardo, Havana. 2008.</p></caption><graphic xlink:href="ISRN.DERMATOLOGY2012-863692.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Response to therapy Hospital Manuel Fajardo, Havana. 2008</p></caption><graphic xlink:href="ISRN.DERMATOLOGY2012-863692.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Distribution of patients according to their response to Glizigen in weeks.</p></caption><graphic xlink:href="ISRN.DERMATOLOGY2012-863692.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Distribution of patients according to their response to podophyllin in weeks.</p></caption><graphic xlink:href="ISRN.DERMATOLOGY2012-863692.004"/></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Photodocumentation. Lesions on the back of the penis.</p></caption><graphic xlink:href="ISRN.DERMATOLOGY2012-863692.005"/></fig><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Photodocumentation. Lesions on the glans penis.</p></caption><graphic xlink:href="ISRN.DERMATOLOGY2012-863692.006"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Distribution of patients according to their ages.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Age groups (years)</th><th align="center" colspan="2" rowspan="1">Glizigen</th><th align="center" colspan="2" rowspan="1">Podophyllin</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">No.</th><th align="center" rowspan="1" colspan="1">
<bold>%</bold>
</th><th align="center" rowspan="1" colspan="1">No.</th><th align="center" rowspan="1" colspan="1">
<bold>%</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">15 to 24</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">
<bold>60.4</bold>
</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">
<bold>60</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">25 to 34</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">20.8</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">20</td></tr><tr><td align="left" rowspan="1" colspan="1">35 to 44</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">6.3</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">45 to 54</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">4.2</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;55</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">8.3</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">4</td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">100</td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Correlation between the cured lesion and the affected area of skin.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Area affected by the lesions</th><th align="center" colspan="2" rowspan="1">Glizigen</th><th align="center" colspan="2" rowspan="1">Podophyllin</th></tr><tr><th align="center" rowspan="1" colspan="1">Cured</th><th align="center" rowspan="1" colspan="1">Not cured</th><th align="center" rowspan="1" colspan="1">Cured</th><th align="center" rowspan="1" colspan="1">Not cured</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">&#x0003c;5 cm<sup>2</sup>
</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;5 cm<sup>2</sup>
</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">CI (95%)</td><td align="center" rowspan="1" colspan="1">
&#x003c7;<sup>2</sup>= 0.0319</td><td align="center" rowspan="1" colspan="1">
<italic>P</italic> = 0.8583</td><td align="center" rowspan="1" colspan="1">
&#x003c7;<sup>2</sup>= 0.4344</td><td align="center" rowspan="1" colspan="1">
<italic>P</italic> = 0.5098</td></tr></tbody></table></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Discomfort associated with the treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Symptoms</th><th align="center" colspan="2" rowspan="1">Glizigen</th><th align="center" colspan="2" rowspan="1">Podophyllin</th></tr><tr><th align="center" rowspan="1" colspan="1">No.</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">No.</th><th align="center" rowspan="1" colspan="1">
<bold>%</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Burning</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">
<bold>30</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Pain</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">Itching</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">None</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">
<bold>82</bold>
</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">
<bold>54</bold>
</td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">100</td></tr></tbody></table></table-wrap></floats-group></article>